|
Aug 6
|
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury
|
|
Jul 23
|
Arch Biopartners’ Phase II AKI prevention trial begins patient recruitment
|
|
Jul 22
|
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)
|
|
Oct 3
|
Closes Units for Debt Settlement
|
|
Jul 29
|
Arch Biopartners Arranges Non-Brokered Private Placement
|
|
Jun 18
|
Arch Biopartners Obtains University of Calgary Ethics Approval to Proceed with Phase II Trial
|
|
Jun 18
|
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
|
|
Apr 16
|
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
|
|
Jan 10
|
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
|
|
Jan 3
|
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
|
|
Dec 21
|
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
|
|
Dec 18
|
Grant of Options to Directors and Officers
|
|
Dec 13
|
Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
|